Google+ Facebook Twitter Twitter

Brain cancer liquid biopsy

Early detection of brain cancer has moved one step closer, according to new research.

New testing technology – the Dxcover Liquid Biopsy – has been shown to be effective even in the earlier days of cancer growth, at a smaller volume and lower stage.

Matt Baker, one of the scientists behind the test, said: “This breakthrough is a watershed moment in the development of early cancer detection. The study demonstrates the effectiveness of our Dxcover Brain Cancer Liquid Biopsy at detecting even the smallest brain tumours, which is great news for the care of future brain cancer patients.”

The study involved 177 patients with varying sizes of brain tumours providing blood samples for analysis by Dxcover.

The samples underwent the spectroscopic analysis under infra-red light and were processed using machine learning software. The test and analysis were found to be effective in identifying brain tumours in patients with gliomas as small as 0.2 cm3.

Dxcover Limited has raised £5.1m in funding to develop its spectroscopy and artificial intelligence technology as a Multi Cancer Early Detection (MCED) Platform.

Image credit | DXcover

Related Articles

My lab: a busy multi-site facility

Biomedical Scientist Team Leader Liam Morrissey gives a guided tour of blood sciences at the University Hospitals of Leicester NHS Trust.

Review, refresh and reimagine

A look back at how the Blood Stocks Management Scheme has evolved over the last two decades, some recent achievements, and what is planned for the next 20 years.

Covid-19 and haemostasis screening: the expected and the unexpected

Senior Biomedical Scientist Clare Wigley and colleagues take us through how their lab processes and workflow changed during the waves of the COVID-19 pandemic.

Just my type: can blood type affect personality?

Senior Lecturer in Biomedical Science at the University of Sunderland Martin Maley explores the issues and puts a theory to the test.